Q1 Earnings Estimate for Prenetics Global Issued By Sidoti

Prenetics Global Limited (NASDAQ:PRE) – Analysts at Sidoti reduced their Q1 2026 earnings estimates for Prenetics Global in a research note issued to investors on Monday, March 30th. Sidoti analyst A. Hantman now forecasts that the company will post earnings of ($0.77) per share for the quarter, down from their previous estimate of ($0.74). The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Sidoti also issued estimates for Prenetics Global’s Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.85) EPS, Q4 2026 earnings at ($1.09) EPS, FY2026 earnings at ($3.55) EPS, Q1 2027 earnings at ($0.12) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at $0.88 EPS, Q4 2027 earnings at $1.45 EPS and FY2027 earnings at $2.16 EPS.

Prenetics Global (NASDAQ:PRE) last announced its quarterly earnings data on Wednesday, February 18th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.22. The company had revenue of $36.60 million for the quarter, compared to analysts’ expectations of $36.15 million. Prenetics Global had a negative return on equity of 19.07% and a negative net margin of 61.33%.

Other equities analysts also recently issued research reports about the company. Lake Street Capital started coverage on Prenetics Global in a research report on Monday, March 16th. They set a “buy” rating and a $29.00 price target on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a report on Thursday, January 22nd. Roth Mkm initiated coverage on shares of Prenetics Global in a research note on Wednesday, February 11th. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Wall Street Zen cut shares of Prenetics Global from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.33.

Prenetics Global Stock Down 3.2%

Shares of NASDAQ PRE opened at $19.32 on Wednesday. Prenetics Global has a twelve month low of $3.09 and a twelve month high of $23.63. The firm has a market cap of $325.16 million, a PE ratio of -4.81 and a beta of 0.36. The business has a fifty day simple moving average of $19.34 and a two-hundred day simple moving average of $16.17.

Prenetics Global declared that its board has initiated a share buyback program on Friday, March 6th that authorizes the company to repurchase $40.00 million in shares. This repurchase authorization authorizes the company to buy up to 15.8% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Institutional Trading of Prenetics Global

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Prenetics Global in the fourth quarter valued at about $1,302,000. 683 Capital Management LLC purchased a new stake in shares of Prenetics Global during the fourth quarter worth about $1,181,000. Aberdeen Group plc acquired a new position in shares of Prenetics Global during the third quarter valued at about $979,000. Millennium Management LLC purchased a new position in shares of Prenetics Global in the 4th quarter valued at approximately $810,000. Finally, Marshall Wace LLP purchased a new position in shares of Prenetics Global in the 4th quarter valued at approximately $788,000. Institutional investors own 25.01% of the company’s stock.

Key Headlines Impacting Prenetics Global

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: Sidoti raised its FY2027 EPS forecast sharply to $2.16 (from $1.65), and upgraded several late‑2027 quarter estimates (Q4 2027 to $1.45, Q3 2027 to $0.88, Q1 2027 improved to -$0.12). This models a path to profitability in FY2027 and is a major positive catalyst for valuation and investor confidence.
• Positive Sentiment: Prenetics announced a strategic partnership with Superpower to integrate clinical‑grade supplementation with blood diagnostics — a consumer product/recurring‑revenue play that could expand addressable market and attach rates for testing services. Article Title
• Neutral Sentiment: Sidoti made a tiny technical lift to FY2026 (to -$3.55 from -$3.56) — effectively unchanged and still well below consensus (~-$3.30), so near‑term profitability remains a stretch per Sidoti’s model.
• Negative Sentiment: Sidoti trimmed several near‑term quarter estimates (Q1 2026 to -$0.77 from -$0.74, Q2 2026 to -$0.85 from -$0.79, Q3 2026 to -$0.85 from -$0.83, and Q2 2027 to -$0.05 from -$0.04). These downgrades suggest anticipated near‑term margin pressure or slower revenue recognition that could weigh on short‑term performance.

Prenetics Global Company Profile

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.